Hepatitis C virus diagnosis and testing

Area of Science:

• Virology
• Infectious Diseases
• Diagnostic Medicine

Background:

• Serological and nucleic acid testing (NAT) have transformed hepatitis C virus (HCV) diagnosis.
• Third-generation anti-HCV enzyme immunoassays (EIAs) are effective for high-prevalence populations but require confirmation in low-prevalence settings to avoid false positives.
• Limitations of EIAs include delayed seroconversion and inability to confirm active infection.

Purpose of the Study:

• To evaluate the role of serological and nucleic acid testing (NAT) in hepatitis C virus (HCV) diagnosis.
• To compare the effectiveness of EIAs and NAT in different prevalence populations.
• To assess the utility of quantitative NAT and HCV genotyping for optimizing antiviral therapy.

Main Methods:

• Utilized third-generation anti-HCV enzyme immunoassays (EIAs) for serological testing.
• Employed nucleic acid testing (NAT) to detect HCV RNA directly in serum, plasma, or tissue.
• Compared the sensitivity, specificity, and reproducibility of commercial NAT assays.

Main Results:

• NAT can confirm active HCV infection and shorten the window between infection and detection to 1-2 weeks.
• Qualitative commercial NAT assays are more sensitive than quantitative assays for confirming active infection.
• HCV infection may become curable with new therapies, impacting transmission and requiring cost-effective diagnostic strategies.

Conclusions:

• A combination of serological tests and NAT is essential for cost-effective HCV diagnosis and monitoring.
• Further evaluation of quantitative NAT and HCV genotyping is needed to optimize antiviral therapy.
• Accurate HCV diagnosis is critical for managing the disease and preventing future transmission.